MP Biomedicals Overview
- Year Founded
-
1959

- Status
-
Acquired/Merged
- Employees
-
648

- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
2
MP Biomedicals General Information
Description
Operator of a life science company intended to produce a diverse portfolio of life science products, fine chemicals and diagnostics. The company is engaged in the production and supply of life science reagents, instruments and diagnostic products to scientists and researchers.
Contact Information
Website
www.mpbio.com(Operating Subsidiary)
Corporate Office
- 3 Hutton Center Drive
- Suite 100
- Santa Ana, CA 92707
- United States
Corporate Office
- 3 Hutton Center Drive
- Suite 100
- Santa Ana, CA 92707
- United States
MP Biomedicals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
MP Biomedicals Comparisons
Industry
Financing
Details
MP Biomedicals Competitors (3)
One of MP Biomedicals’s 3 competitors is Illumina, a Formerly VC-backed company based in San Diego, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Illumina | Formerly VC-backed | San Diego, CA | ||||
Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
3B BlackBio Biotech | Corporate Backed or Acquired | Bhopal, India |
MP Biomedicals Patents
MP Biomedicals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9962717-B1 | Instrument for automated sample preparation by combination homogenization and clarification | Inactive | 31-Jul-2017 | ||
US-D660453-S1 | Cell and tissue homogenizer | Active | 20-Apr-2011 | ||
EP-1480946-A2 | A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity | Inactive | 09-Jul-2001 | ||
US-20030114529-A1 | Ho-nh-(c=o)-ch2-ch(-ch2-ch(ch3)2)-(c=o)-v-,v=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation | Inactive | 09-Jul-2001 | ||
CA-2453346-A1 | A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity | Inactive | 09-Jul-2001 | C07K14/78 |
MP Biomedicals Signals
MP Biomedicals Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
MP Biomedicals Acquisitions (2)
MP Biomedicals’s most recent deal was a Merger/Acquisition with ICP Biotechnology. The deal was made on 14-Jun-2010.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
ICP Biotechnology | 14-Jun-2010 | Merger/Acquisition | Biotechnology | ||
Qbiogene | 27-Sep-2004 | Merger/Acquisition | Biotechnology |
MP Biomedicals FAQs
-
When was MP Biomedicals founded?
MP Biomedicals was founded in 1959.
-
Where is MP Biomedicals headquartered?
MP Biomedicals is headquartered in Santa Ana, CA.
-
What is the size of MP Biomedicals?
MP Biomedicals has 648 total employees.
-
What industry is MP Biomedicals in?
MP Biomedicals’s primary industry is Diagnostic Equipment.
-
Is MP Biomedicals a private or public company?
MP Biomedicals is a Private company.
-
What is the current valuation of MP Biomedicals?
The current valuation of MP Biomedicals is
. -
What is MP Biomedicals’s current revenue?
The current revenue for MP Biomedicals is
. -
Who are MP Biomedicals’s investors?
Bausch Health Companies has invested in MP Biomedicals.
-
Who are MP Biomedicals’s competitors?
Illumina, Foundation Medicine, and 3B BlackBio Biotech are competitors of MP Biomedicals.
-
When was MP Biomedicals acquired?
MP Biomedicals was acquired on 21-Oct-2015.
-
Who acquired MP Biomedicals?
MP Biomedicals was acquired by Valiant Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »